What is the 13F Pro Quality Score for SIGA?

13F Pro ranks SIGA TECHNOLOGIES INC (SIGA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SIGA's current score at https://13fpro.ai/company/SIGA (free sign-up required for the full ranking).

Which hedge funds own the most SIGA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SIGA include BlackRock,, DIMENSIONAL FUND ADVISORS, AltraVue Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SIGA as soon as new 13F filings post.

Where does 13F Pro source SIGA data?

All SIGA TECHNOLOGIES INC fundamentals and ownership data come directly from SEC EDGAR. SIGA TECHNOLOGIES INC files with the SEC under CIK 1010086. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SIGA in?

SIGA TECHNOLOGIES INC (SIGA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives SIGA's revenue?

Per SIGA TECHNOLOGIES INC's latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Research and development ($5.8M, +81% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/SIGA.

What are SIGA's largest expenses?

SIGA TECHNOLOGIES INC's latest 10-Q reports these as the largest expense items: Cost of sales and supportive services ($20.5M, -20% YoY); Research and development ($8.3M, +5% YoY); Selling, general and administrative ($9.8M, -12% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (six months ended June 30, 2026).

How often is SIGA research updated on 13F Pro?

SIGA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SIGA TECHNOLOGIES INC(SIGA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1010086 SIGA stock profile & AI dashboard →

13F Pro Quality Score

14.9/100

Rank #2,861 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

10.3/100

Profitability

21.6/100

Balance Sheet

30.3/100

Earnings Quality

1.3/100

Free Cash Flow

10.6/100

Institutional Flow

35.7/100

Revenue Scale

9.5/100

Dilution Risk

28.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SIGA Scores 15/100

exact factor attribution · 2026-09-11

SIGA's composite is held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-0.7 pts

36th pct

Shareholder dilution

-1.1 pts

28th pct

Capital efficiency

-2.0 pts

30th pct

Earnings growth

-2.3 pts

4th pct

Profitability

-4.3 pts

22th pct

Earnings quality

-4.9 pts

1th pct

Free cash flow

-5.9 pts

11th pct

Scale

-6.1 pts

10th pct

Revenue growth

-7.9 pts

10th pct

Latest change (2026-08-06): 74 → 25 · ↓ Revenue growth 91→2; ↓ Profit margin 90→11

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in SIGA

Events flagged as statistical outliers against SIGA's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
SIGA quality score dropped 49 points (74→25) on a new filing
View source filing →

SIGA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for SIGA TECHNOLOGIES INC (SIGA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SIGA at 14.9/100 on a 32-signal composite quality model, placing it at rank #2,861 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.3) and revenue scale (9.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SIGA TECHNOLOGIES INC reports quarterly revenue of $41.0M, net income of $12.5M. Top institutional holders of SIGA by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, AltraVue Capital, based on the most recent SEC filings. SIGA trades on the Nasdaq exchange and files with the SEC under CIK 1010086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SIGA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SIGA TECHNOLOGIES INC directly from SEC EDGAR. SIGA TECHNOLOGIES INC's 13F Pro composite quality score has ranged between 15 and 76 since 2021, currently 14.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about SIGA TECHNOLOGIES INC

Quirks, history, and lore behind SIGA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Annual revenue in the range of tens of millions of dollars, almost entirely dependent on a single product and government procurement contracts.
3
The History
Founded in the late 1990s, the company spent years in development before landing a drug approval tied to one of the most feared bioterrorism threats on the planet.
4
The Secret
Its primary customer isn't a hospital chain or pharmacy — it's the U.S. federal government, which stockpiles its drug in the Strategic National Stockpile.
5
The Lore
When monkeypox outbreaks spike anywhere in the world, this company's stock price tends to spike right along with them — investors treat it as a biodefense barometer.
6
The Giveaway
Its flagship drug TPOXX (tecovirimat) is the only FDA-approved oral treatment for smallpox — a disease officially eradicated, yet still worth defending against.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving SIGA's Business? Latest 10-Q Breakdown

AI-extracted from SIGA TECHNOLOGIES INC's 10-Q filed 2026-08-06 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

SIGA revenues fell 46% YoY to $47.2M in H1 2026 as U.S. Government TPOXX orders declined sharply, though international sales of $13M and R&D revenue growth partially offset the drop.

Biggest Revenue Drivers

Research and development$5.8M+81% YoY

Increase in billable activities under the 19C BARDA Contract

Biggest Revenue Drivers

Total revenue: $47.2M-46% YoY

Research and development$5.8M+81% YoY

Increase in billable activities under the 19C BARDA Contract

Largest Expense Items

Cost of sales and supportive services$20.5M-20% YoY

Primarily associated with manufacture and delivery of IV TPOXX to U.S. Government and oral TPOXX to international countries

Research and development$8.3M+5% YoY

Increase in direct vendor costs under 19C BARDA Contract and EMA referral procedure costs for mpox, offset by lower self-funded R&D

Selling, general and administrative$9.8M-12% YoY

Lower corporate expenses in consulting, professional services, and international business development, partially offset by higher compensation

Margins: Gross margin on product sales improved as IV TPOXX revenue mix shifted, with lower cost of sales as a percentage of revenue. Operating income declined 80% YoY to $8.6M as the significant revenue decline outpaced SG&A expense reductions.

Watch Items from the Filing

U.S. Government represents majority of revenue via 19C BARDA Contract; H1 2026 U.S. product revenue declined 81% YoY to $28.0M as contract deliveries slowed.
19C BARDA Contract contemplates ~$630M in total payments, of which ~$545.2M exercised options remain undelivered; IV TPOXX expected gross margin below 40%.
EMA/MHRA removed mpox indication from Tecovirimat-SIGA (May 2026) following failed clinical trials (PALM007, STOMP); label now restricted to smallpox, cowpox, vaccinia complications.
New MENA license agreement with Hikma (March 2026) and international sales of $13M in H1 2026 represent emerging diversification beyond U.S. Government procurement.
Cash declined $37.4M to $117.6M in H1 2026 due to $43.3M special dividend paid in April 2026 and reduced operating cash generation ($6.5M vs $70.1M YoY).

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$41.0M

Net Income

Q2 2026

$12.5M

ROIC

Q2 2026

33.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-31.8% YoY

$94.6MFY 2025

FY22 $110.8MFY23 $139.9MFY24 $138.7MFY25 $94.6M

Net Income

-60.7% YoY

$23.3MFY 2025

FY22 $33.9MFY23 $68.1MFY24 $59.2MFY25 $23.3M

Operating Income

-66.1% YoY

$23.7MFY 2025

FY22 $42.7MFY23 $83.6MFY24 $70.0MFY25 $23.7M

EPS (Diluted)

-61.0% YoY

$0.32FY 2025

FY22 $0.46FY23 $0.95FY24 $0.82FY25 $0.32

Total Assets

-10.2% YoY

$219.5MFY 2025

FY22 $195.0MFY23 $254.4MFY24 $244.3MFY25 $219.5M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-10.8% YoY

$43.5MFY 2025

FY22 $41.6MFY23 $94.8MFY24 $48.8MFY25 $43.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$94.6M -31.8%	$138.7M -0.9%	$139.9M +26.3%	$110.8M -17.1%	$133.7M +7.0%	$125.0M
Net Income	$23.3M -60.7%	$59.2M -13.0%	$68.1M +100.8%	$33.9M -51.2%	$69.5M +23.3%	$56.3M
Operating Income	$23.7M -66.1%	$70.0M -16.3%	$83.6M +95.8%	$42.7M -52.1%	$89.1M +5.4%	$84.5M
EPS (Diluted)	$0.32 -61.0%	$0.82 -13.7%	$0.95 +106.5%	$0.46 -49.5%	$0.91 +28.2%	$0.71
Total Assets	$219.5M -10.2%	$244.3M -3.9%	$254.4M +30.4%	$195.0M -9.2%	$214.7M +43.3%	$149.8M
Total Debt	—	—	—	—	—	$0.00
Operating Cash Flow	$43.5M -10.8%	$48.8M -48.6%	$94.8M +127.8%	$41.6M +262.0%	$11.5M -83.9%	$71.5M

Get alerted when SIGA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SIGA TECHNOLOGIES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SIGA

BlackRock, Inc.
$15.2M4,186,282 sh
DIMENSIONAL FUND ADVISORS LP
$9.9M2,719,568 sh
AltraVue Capital, LLC
$8.5M2,327,144 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.2M1,712,701 sh
AMERICAN CENTURY COMPANIES INC
$5.5M1,506,065 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$5.4M1,474,817 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.2M1,417,092 sh
FIRST WILSHIRE SECURITIES MANAGEMENT INC
$4.9M1,339,883 sh
AQR CAPITAL MANAGEMENT LLC
$4.5M1,245,992 sh
STATE STREET CORP
$4.1M1,133,989 sh

Fund	Value	Shares
BlackRock, Inc.	$15.2M	4,186,282
DIMENSIONAL FUND ADVISORS LP	$9.9M	2,719,568
AltraVue Capital, LLC	$8.5M	2,327,144
VANGUARD CAPITAL MANAGEMENT LLC	$6.2M	1,712,701
AMERICAN CENTURY COMPANIES INC	$5.5M	1,506,065
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$5.4M	1,474,817
GEODE CAPITAL MANAGEMENT, LLC	$5.2M	1,417,092
FIRST WILSHIRE SECURITIES MANAGEMENT INC	$4.9M	1,339,883
AQR CAPITAL MANAGEMENT LLC	$4.5M	1,245,992
STATE STREET CORP	$4.1M	1,133,989

Companies Similar to SIGA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

OSUR

ORASURE TECHNOLOGIES INC

AI score

Similar quality profile · 4 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Significant Wealth Partners LLC Headlands Technologies LLC

ARCT

Arcturus Therapeutics Holdings Inc.

AI score

Similar quality profile · 4 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Abel Hall, LLC China Universal Asset Management Co., Ltd.

NVAX

NOVAVAX INC

AI score

Similar quality profile · 7 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC MARTINGALE ASSET MANAGEMENT L P Atom Investors LP

ENTA

ENANTA PHARMACEUTICALS INC

AI score

Similar quality profile · 4 shared holders

MARTINGALE ASSET MANAGEMENT L P Headlands Technologies LLC China Universal Asset Management Co., Ltd.

ABUS

Arbutus Biopharma Corp

AI score

Similar quality profile · 5 shared holders

MARTINGALE ASSET MANAGEMENT L P EntryPoint Capital, LLC Abel Hall, LLC

ACNT

ASCENT INDUSTRIES CO.

AI score

Similar quality profile · 1 shared holders

R Squared Ltd

AMPH

Amphastar Pharmaceuticals, Inc.

AI score

Similar quality profile · 11 shared holders

ROYCE & ASSOCIATES LP LSV ASSET MANAGEMENT DENALI ADVISORS LLC

OPK

OPKO HEALTH, INC.

AI score

Similar quality profile · 2 shared holders

WASHINGTON GROWTH STRATEGIES LLC Headlands Technologies LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SIGA on your watchlist

Track score changes the day SIGA TECHNOLOGIES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SIGA a good stock to buy?

13F Pro's AI-powered analysis of SIGA TECHNOLOGIES INC (SIGA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SIGA are available on the SIGA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SIGA is classified as a small company.

Which hedge funds own SIGA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SIGA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SIGA TECHNOLOGIES INC's investment landscape.